📗 Cite This Artifact
Metabolic Therapy for Neurodegeneration
Metabolic Therapy for Neurodegeneration
Overview
Metabolic Therapy for Neurodegeneration
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Metabolic Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">AC-1202 (AXONA)</td>
<td>20-30g daily</td>
</tr>
<tr>
<td class="label">Ketone ester</td>
<td>25-50g daily</td>
</tr>
<tr>
<td class="label">MCT oil</td>
<td>20-60g daily</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT00670146</td>
<td>Ketogenic diet</td>
</tr>
<tr>
<td class="label">NCT02531438</td>
<td>MCT oil (Axona)</td>
</tr>
<tr>
<td class="label">NCT03400124</td>
<td>Ketone ester</td>
</tr>
<tr>
<td class="label">NCT04237411</td>
<td>Fasting mimetic</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">NCT03963206</td>
<td>Ketogenic diet</td>
</tr>
<tr>
<td class="label">NCT05237505</td>
<td>MCT supplementation</td>
</tr>
<tr>
<td class="label">NCT05485640</td>
<td>Metabolic modulator</td>
</tr>
</table>
Metabolic therapy encompasses therapeutic approaches that target metabolic dysfunction in neurodegenerative diseases. These strategies aim to improve brain energy metabolism, enhance mitochondrial function, and correct metabolic deficits that contribute to neuronal dysfunction and death. Key approaches include ketogenic diets, metabolic modulators, glucose metabolism enhancers, and fasting mimetics. This therapy is particularly relevant for Alzheimer's disease (AD) and Parkinson's disease (PD), both of which exhibit well-documented metabolic impairments. [@henderson2009]
Mechanism of Action
Brain Energy Metabolism in Neurodegeneration
Neurodegenerative diseases are characterized by impaired cerebral glucose metabolism: [@krikorian2012]
- Alzheimer's Disease: Regional brain hypometabolism (especially in posterior cingulate and hippocampus) precedes clinical symptoms by decades. Insulin resistance and impaired glucose transport contribute to energy deficits.
- Parkinson's Disease: Complex I deficiency in mitochondria leads to impaired oxidative phosphorylation and ATP depletion in dopaminergic [neurons](/entities/neurons).
Metabolic Therapy Mechanisms
Therapeutic Approaches
Ketogenic Diet and Ketone Supplementation
The ketogenic diet (KD) mimics fasting metabolism by shifting energy production from glucose to ketone bodies: [@pawelzik2022]
- Classic Ketogenic Diet: 70-80% fat, 15-20% protein, 5-10% carbohydrate
- Medium-Chain Triglyceride (MCT) Oil: Directly produces ketones in the liver
- Exogenous Ketones: Beta-hydroxybutyrate (BHB) supplements
Metabolic Modulators
- Dichloroacetate (DCA): Activates pyruvate dehydrogenase complex
- Metformin: AMPK activator; improves insulin sensitivity
- Thiazolidinediones: PPAR-γ agonists for metabolic regulation
Fasting and Fasting Mimetics
- Intermittent Fasting: 16:8 or 5:2 protocols
- Caloric Restriction: 20-30% reduction in daily calories
- Rapamycin: [mTOR](/mechanisms/mtor-signaling-pathway) inhibitor with fasting-like effects
- Resveratrol: SIRT1 activator
Clinical Evidence
Alzheimer's Disease
Parkinson's Disease
Key Findings
- Ketogenic interventions show consistent cognitive/motor improvements
- Benefits may be more pronounced in patients without APOE4 allele
- Adherence is challenging; dropout rates of 20-40% in studies
- Metabolic biomarkers (ketone levels, glucose metabolism) correlate with clinical response
Metabolic Biomarkers for Patient Selection
Effective patient selection requires metabolic profiling:
Safety and Considerations
Ketogenic Diet Risks
- Hyperlipidemia: Monitor cholesterol and triglycerides
- Kidney Stones: Increased risk; maintain hydration
- Nutrient Deficiencies: Supplement vitamins and minerals
- Acidosis: Rare in adults; monitor pH and electrolytes
Contraindications
- Pancreatitis
- Liver failure
- Severe renal disease
- History of eating disorders
- Porphyria
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Ketogenic Diet](/therapeutics/ketogenic-diet)
- [Mitochondrial Therapeutics](/therapeutics/mitochondrial-therapeutics)
- [Caloric Restriction Mimetics](/therapeutics/caloric-restriction-mimetics)
- [Metabolic Syndrome](/mechanisms/metabolic-syndrome-neurodegeneration)
External Links
- [PubMed: Metabolic Therapy Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=ketogenic+alzheimer+parkinson)
- [ClinicalTrials.gov](https://clinicaltrials.gov)
- [Charlie Foundation - Ketogenic Diet Resources](https://charliefoundation.org/)
References
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
Related Analyses:
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
- [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
- [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
- [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | therapeutics-metabolic-therapy |
| kg_node_id | None |
| entity_type | therapeutic |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-431bb5163ad1 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-metabolic-therapy'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-therapeutics-metabolic-therapy?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Metabolic Therapy for Neurodegeneration](http://scidex.ai/artifact/wiki-therapeutics-metabolic-therapy)
http://scidex.ai/artifact/wiki-therapeutics-metabolic-therapy